All In Biotech

Drug Trial Radar · NCT07850453

Vortosiran for VTE Prevention

Randomized, Double-blind, Phase II Trial of Vortosiran to Evaluate Safety, Tolerability, and Pharmacodynamic Efficacy in Participants With Prior Venous Thromboembolism After Completion of Initial Anticoagulant Therapy (Cohort A) and in Cancer Patients at High Risk of Venous Thromboembolism (Cohort B)

Last checked: Nov 19, 2026Latest source record: Sep 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 150 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

150

Planned (sponsor's estimate)

Start

Oct 2026

Primary completion

Jul 2027

Study completion May 2028

Sponsor

Lead sponsor
Ribocure Pharmaceuticals ABIndustry
Sponsor type
Industry
Collaborators
Fortrea
First posted
Sep 30, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Blood clots remain a serious cause of illness and death. Long-term treatment and prevention of these clots with blood thinners is often limited by bleeding risk, drug interactions, and daily dosing, leading many patients to stop treatment early. Both cancer and chemotherapy further increase the risk of clot formation. Vortosiran is an injectable therapy that lowers Factor XI (one of the body's natural clotting helpers) production in the liver, leading to a strong and long-lasting reduction in blood clotting activity with less risk of bleeding compared to current available treatments. Studies conducted so far have shown that vortosiran is safe and shows a dose-dependent Factor XI suppression (that is, a higher dose results in a higher level of suppression) that lasts for several months, supporting testing using a limited number of injections in patients who are at higher risk of blod clot formation. This study aims to study how safe and effective vortosiran is in patients who have had blood clots in the past and in cancer patients who are at high risk of developing blood clots.

Conditions

  • Venous Thromboembolism (VTE)
  • Cancer
  • Pulmonary Embolism (Diagnosis)

Interventions

  • VortosiranDrug

    Vortosiran, active drug.

  • PlaceboDrug

    Placebo that is identical in appearance of active IMP.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Primary objectiveTime frame: At Week 8
  2. Primary endpointTime frame: Baseline to Week 8.

Locations

30 sites in 4 countries. Site status is shown where the registry gives one.

  • Multiprofile Hospital For Active Treatment - Pazardzhik AD

    Pazardzhik, Bulgaria

  • Specialized Hospital for Active Treatment in Cardiology - Medica Cor EAD

    Rousse, Bulgaria

  • Acibadem City Clinic Tokuda University Hospital EAD

    Sofia, Bulgaria

  • Multiprofile Hospital for Active Treatment "National Cardiology Hospital" EAD

    Sofia, Bulgaria

  • Multiprofile Hospital for Active Treatment "National Cardiology Hospital" EAD

    Sofia, Bulgaria

  • University Hospital for Active Treatment and Emergency Medicine N.I. Pirogov EAD

    Sofia, Bulgaria

  • University Multiprofile Hospital for Active Treatment "Alexandrovska"

    Sofia, Bulgaria

  • Multiprofile District Hospital for Active Treatment "Dr. Stefan Cherkezov" AD

    Veliko Tarnovo, Bulgaria

  • Centre Oncologie Radiotherapie (CORT 37)

    Chambray-lès-Tours, France

  • Louis-Mourier (AP-HP)

    Colombes, France

  • CHU de Grenoble

    Grenoble, France

  • Hôpital Européen Georges Pompidou (HEGP)

    Paris, France

  • Cardiology Office Individual Specialist Medical Practice Elżbieta Dułak

    Gdynia, Poland

  • Oddział Kardiologii SPS Szpital Zachodni im św Jana Pawła iI

    Grodzisk Mazowiecki, Poland

  • Uniwersytet Jagiellonski Collegium Medicum

    Krakow, Poland

  • "Department of Cardiology European Health Center Otwock"

    Otwock, Poland

  • University Clinical Research Support Center of Medical University in Poznan

    Poznan, Poland

  • Clinical Oncology Department, Mazowiecki Szpital Wojewódzki

    Siedlce, Poland

  • Aidport Sp. z o.o.

    Skorzewo, Poland

  • Zachodniopomorskie Centrum Onkologii

    Szczecin, Poland

  • Centrum Medyczne LUX MED sp zoo ul 1 Sierpnia 8, 02-143 Warszawa

    Warsaw, Poland

  • Klinika Sienna Sp. z o.o.

    Warsaw, Poland

  • Maria Skłodowska-Curie National Research Institute of Oncology

    Warsaw, Poland

  • Gral Medical - Oncofort Pitesti

    Piteşti, Romania

  • Satu Mare County Emergency Hospital

    Satu Mare, Romania

  • Spitalul European Polisano - Constitutiei Sibiu

    Sibiu, Romania

  • Sigmedical Services S.R.L.

    Suceava, Romania

  • Centrul Medical Cardiomed

    Târgu Mureş, Romania

  • Spitalul Clinic Judeţean Mureş

    Târgu Mureş, Romania

  • Institutului de Boli Cardiovasculare Timişoara

    Timișoara, Romania

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.